Search

EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death

EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalisation for heart-failure and cardiovascular death. Find out more here.

Jardiance® (empagliflozin) now approved in India for treatment of chronic kidney disease

Jardiance® (empagliflozin) now approved in India

Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India

Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India. Click here to find out and learn more.

EMPRISE

Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care. Click here to find out more information.

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug.

Empagliflozin safety and all-cause mortality

1988-2015

Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. Learn more here.

About Us

Human Health

Animal Health